Last updated on December 2019

Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin FlexPro ) in Growth Hormone Treatment na ve Pre-pubertal Children With Growth Hormone Deficiency


Brief description of study

This trial is conducted globally. The aim of the trial is to investigate efficacy and safety of once-weekly NNC0195-0092 (somapacitan) treatment compared to daily growth hormone treatment (Norditropin FlexPro) in growth hormone treatment nave pre-pubertal children with growth hormone deficiency.

The trial consists of a 26 week main trial period, followed by a 26 week extension trial period, a 104 week safety extension period, a 208 week longterm safety extension trial period and a 30 day follow up period. Participants receive NNC0195-0092 (somapacitan) (0.04 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods. Two additional age groups, cohort II (age below 2 years and 26 weeks at screening) and cohort III (above 9 years (girls)/ above 10 years (boys) and equal to or below 17 years at screening) are included in the 208 week long-term safety extension trial period only.

Clinical Study Identifier: NCT02616562

Find a site near you

Start Over

Novo Nordisk Investigational Site

Minneapolis, MN United States
  Connect »

Novo Nordisk Investigational Site

New Brunswick, NJ United States
  Connect »

Novo Nordisk Investigational Site

Philadelphia, PA United States
  Connect »